Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.

Autor: Cortés-Hernández J; Rheumatology Department, Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: fina.cortes@vhir.org., Marras Fernández-Cid C; Rheumatology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., Andreu Sánchez JL; Rheumatology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain., Calvo Alén J; Rheumatology Department, Hospital Universitario de Araba, Vitoria, Spain., García-Aparicio AM; Rheumatology Department, Hospital Universitario de Toledo, Toledo, Spain., Díez Álvarez E; Rheumatology Department, Hospital Universitario de León, León, Spain., Hidalgo Bermejo FJ; Medical Department, GSK, Madrid, Spain., Coronell C; Primary Care Medical Center of Vallirana, Barcelona, Spain, formerly Medical Department, GSK, Madrid, Spain., Perna A; Specialty Franchise, GSK, London, UK., Ordi Ros J; Rheumatology Department, Hospital Vall d'Hebron, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2023 Jun-Jul; Vol. 19 (6), pp. 312-318.
DOI: 10.1016/j.reumae.2023.05.003
Abstrakt: Introduction and Objectives: This OBSErve Spain study, a part of the international OBSErve programme, evaluated belimumab real-world use and effectiveness following 6 months of treatment in patients with active systemic lupus erythematosus (SLE) in clinical practice in Spain.
Materials and Methods: In this retrospective, observational study (GSK Study 200883), eligible patients with SLE receiving intravenous belimumab (10mg/kg) had their disease activity (physician assessed), SELENA-SLEDAI scores, corticosteroid use, and healthcare resource utilisation (HCRU), assessed after 6 months of treatment versus index (belimumab initiation) or 6 months pre-index.
Results: Overall, 64 patients initiated belimumab, mainly due to ineffectiveness of previous treatments (78.1%) and to reduce corticosteroid use (57.8%). Following 6 months of treatment, 73.4% of patients achieved ≥20% overall clinical improvement, while only 3.1% of patients worsened. Mean (standard deviation, SD) SELENA-SLEDAI score decreased from 10.1 (6.2) at index to 4.5 (3.7) 6 months post-index. HCRU decreased from 6 months pre-index to 6 months post-index, with fewer hospitalisations (10.9% vs 4.7% patients) and ER visits (23.4% vs 9.4% patients). Mean (SD) corticosteroid dose decreased from 14.5 (12.5)mg/day at index to 6.4 (5.1)mg/day 6 months post-index.
Conclusions: Patients with SLE receiving belimumab for 6 months in real-world clinical practice in Spain experienced clinical improvements and a reduction in HCRU and corticosteroid dose.
(Copyright © 2022 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: